Aquestive Therapeutics Reports Q3 2026 Net Loss of $16.5M
Aquestive Therapeutics, Inc. filed its Form 10-Q for the period ending September 30, 2026. The company reported a net loss of $16.496 million for the third quarter of 2026, an increase from the $15.446 million loss in the same period of 2025. Total revenues for the quarter decreased to $7.557 million from $12.807 million year-over-year. For the nine months ended September 30, 2026, the net loss was $47.417 million, an improvement from $51.924 million in 2025, while revenues increased to $35.822 million from $31.530 million. Cash and cash equivalents stood at $90.349 million as of September 30, 2026.
Key Highlights
- Aquestive Therapeutics reported a net loss of $16.496 million for Q3 2026, compared to $15.446 million in Q3 2025.
- Nine-month net loss for 2026 was $47.417 million, down from $51.924 million in the same period of 2025.
- Total revenues for Q3 2026 were $7.557 million, a decrease from $12.807 million in Q3 2025.
- Nine-month revenues for 2026 were $35.822 million, an increase from $31.530 million in the same period of 2025.
- Cash and cash equivalents decreased to $90.349 million as of September 30, 2026, from $121.169 million as of December 31, 2025.
- Total assets decreased to $119.327 million as of September 30, 2026, from $160.425 million as of December 31, 2025.
- Total liabilities decreased to $190.151 million as of September 30, 2026, from $194.087 million as of December 31, 2025.
Price Impact
More from AQST
Aquestive Therapeutics Furnishes Investor Presentation on Anaphylm and AQST-108
Aquestive Therapeutics Q3 Loss Widens to $16.5M; Anaphylm NDA PDUFA Date Set
Aquestive Therapeutics Appoints Richard Daly to Board of Directors